Economic Evaluation of Talimogene Laherparepvec Plus Ipilimumab vs Ipilimumab Alone for Unresectable Melanoma

This economic evaluation assesses the cost-effectiveness of talimogene laherparepvec plus ipilimumab combination therapy vs ipilimumab monotherapy in patients with advanced unresectable melanoma from the perspective of public and private US payers.

https://ift.tt/2KqqI1E